ALPS Advisors’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-41,149
| Closed | -$828K | – | 1197 |
|
|
2026
Q1 | $828K | Sell |
41,149
-355
| -0.9% | -$5.72K | ﹤0.01% | 610 |
|
|
2025
Q4 | $670K | Buy |
+41,504
| New | +$550K | ﹤0.01% | 662 |
|
|
2023
Q4 | – | Sell |
-25,338
| Closed | -$244K | – | 991 |
|
|
2023
Q3 | $244K | Buy |
25,338
+222
| +0.9% | +$2.27K | ﹤0.01% | 926 |
|
|
2023
Q2 | $226K | Buy |
+25,116
| New | +$232K | ﹤0.01% | 969 |
|
|
2022
Q4 | – | Sell |
-13,433
| Closed | -$195K | – | 1062 |
|
|
2022
Q3 | $195K | Sell |
13,433
-1,128
| -8% | -$15.8K | ﹤0.01% | 1004 |
|
|
2022
Q2 | $143K | Sell |
14,561
-10,658
| -42% | -$118K | ﹤0.01% | 1013 |
|
|
2022
Q1 | $372K | Sell |
25,219
-3,055
| -11% | -$43.9K | ﹤0.01% | 550 |
|
|
2021
Q4 | $374K | Buy |
+28,274
| New | +$450K | ﹤0.01% | 723 |
|
|
2020
Q4 | – | Sell |
-22,822
| Closed | -$287K | – | 861 |
|
|
2020
Q3 | $287K | Sell |
22,822
-1,528
| -6% | -$19.1K | ﹤0.01% | 532 |
|
|
2020
Q2 | $295K | Sell |
24,350
-8,040
| -25% | -$85.5K | ﹤0.01% | 562 |
|
|
2020
Q1 | $248K | Sell |
32,390
-3,774
| -10% | -$50.9K | ﹤0.01% | 574 |
|
|
2019
Q4 | $644K | Buy |
+36,164
| New | +$472K | 0.01% | 476 |
|
Other funds holding KALV
ALPS Advisors's KALV Position: Q2 2026 in Review
ALPS Advisors sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 41,149 shares — an estimated $828K sold.
ALPS Advisors first reported a position in KALV in Q4 2019 and held it in 12 quarters. The position peaked at $828K in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- ALPS Advisors reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- ALPS Advisors sold 41,149 KalVista Pharmaceuticals shares in Q2 2026, an estimated $828K.
- ALPS Advisors first reported a position in KalVista Pharmaceuticals in Q4 2019 and held it in 12 quarters.
- ALPS Advisors's KalVista Pharmaceuticals position peaked at $828K in Q1 2026.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.